KEY FINDINGS The IBS-C drug market in Europe is predicted to register a CAGR of 9.38% during the estimated period, 2020-2028. Europe has the largest market share in the market. The demand for the market is growing, due to the highest number of patients suffering from IBS in the region.
MARKET INSIGHTS In order to survey the Europe IBS- C drug market further, the European region is segregated into countries such as France, Poland, Italy, Belgium, Russia, the UK, Germany, and the rest of Europe that include countries like Spain and others.The Russian pharmaceutical industry is being considered by US exporters, and has huge potential, and can be distinguished into over the counter (OTC) medicines and prescription drugs.
The pharmaceutical industry accounts for 1.2% of GDP and 22.1% of Russia’s healthcare expenditure. Prescription drug sales dominated sales until 2018, which represented 62.3% of sales. In Belgium, healthcare expenditure accounted for 10% of GDP in 2016 and remained stable over the years. In order to ensure good quality and effective medicines used currently, the pharmaceutical industry is heavily regulated. In countries like Poland, the growing elderly population and the rise in the number of gastrointestinal diseases and colorectal cancer are expected to fuel the overall growth of the market. Though Poland’s pharmaceutical market lags behind most Western European nations, the market records steady growth, owing to the stability and bright outlook of the country that attracts most global pharmaceutical companies. In Spain, IBD affects 7.8% of the population and twice the number of women compared to men.
COMPETITIVE INSIGHTS AstraZeneca, Abbott Laboratories, Ferring BV, The Menarini Group, Bama-Geve, S.L.U., etc. are some of the major companies operating in the market.
Our report offerings include: • Explore key findings of the overall market • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions • Market Segmentation cater to a thorough assessment of key segments with their market estimations • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Companies mentioned 1. CATALENT PHARMACEUTICALS SOLUTIONS 2. ABBOTT LABORATORIES 3. NOVARTIS PHARMA AG 4. ASTELLAS PHARMACEUTICALS 5. ARDELYX, INC. 6. SYNTHETIC BIOLOGICS, INC. 7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED 8. BAMA-GEVE, SLU 9. FERRING BV 10. IRONWOOD PHARMACEUTICALS, INC. 11. SALIX PHARMACEUTICALS LTD. 12. NORGINE B.V. 13. PROMETHEUS LABORATORIES, INC. 14. ALBIREO PHARMA, INC. 15. YUHAN CORP. 16. ASTRAZENECA PLC 17. THE MENARINI GROUP 18. ONO PHARMACEUTICAL CO. LTD. 19. ACTAVIS NORDIC A/S
Our reports have been used by over 10K customers, including:
Antacids Market Research Report by Formulation (Liquid, Powder, and Tablet), by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents, and Proton Pump Inhibitor), by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Antacids Market is expected to grow from USD 6,602.69...
218 pages •
By Asia Market Information & Development Company
• Jun 2020
China’s demand for Digestive Remedies has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
Gastrointestinal Drugs Market Research Report by Drug Category (Acid Neutralizers, Anti-Inflammatory, Antiemetic and Antinauseants, Biologics, and Laxatives and Anti-diarrheal), by Route of Administration (Oral, Parenteral, and Rectal), by Disease Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 The...
Emesis (Vomiting) Global Clinical Trials Review, H1, 2020 Summary Clinical trial report, “Emesis (Vomiting) Global Clinical Trials Review, H1, 2020" provides an overview of Emesis (Vomiting) Clinical trials scenario.This report provides top line data relating to the clinical trials on Emesis (Vomiting). Report...
Cholera - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H2 2020, provides an overview of the Cholera (Infectious Disease) pipeline landscape. Cholera is an acute infectious disease caused by a bacterium, Vibrio...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.